Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

625.60
+8.601.39%
Post-market: 602.33-23.2700-3.72%18:52 EDT
Volume:901.48K
Turnover:560.85M
Market Cap:68.39B
PE:16.32
High:628.00
Open:613.53
Low:610.10
Close:617.00
Loading ...

BUZZ-US drugmakers fall after Trump announces reciprocal tariffs

Reuters
·
1 hour ago

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Yesterday

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Regeneron Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $780 From $834

THOMSON REUTERS
·
01 Apr

Regeneron Pharma Is Maintained at Overweight by JP Morgan

Dow Jones
·
31 Mar

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks
·
31 Mar

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

Zacks
·
31 Mar

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $1,000 From $1,100, Maintains Overweight Rating

MT Newswires Live
·
31 Mar

U.S. RESEARCH ROUNDUP- Braze, Home Bancshares, Union Pacific

Reuters
·
31 Mar

Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment

TIPRANKS
·
28 Mar

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

GlobeNewswire
·
28 Mar

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

GlobeNewswire
·
28 Mar

Regeneron Pharmaceuticals Inc. Stock Slips 4.1%, Underperforms Competitors

Dow Jones
·
26 Mar

Press Release: Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

Dow Jones
·
26 Mar

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

Zacks
·
25 Mar

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?

Insider Monkey
·
25 Mar

BUZZ-Unity Biotechnology falls as eye disease treatment fails in mid-stage trial

Reuters
·
24 Mar

Regeneron Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
21 Mar

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

StockStory
·
20 Mar